Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867309 | 0.81 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL29561825 | 0.81 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL17361975 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL23376904 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL30646100 | 0.77 | GRM5 (0.47) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL23376905 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL23376853 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL3894956 | 0.77 | CYP2C19 (0.54) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL29526263 | 0.77 | GRM5 (0.51) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL18248704 | 0.77 | GRM5 (0.48) | GRM5ALDH1A1NPSR1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115010712-A | TDO2 inhibitors | 基因泰克公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-0489379-B1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5310914-A | Imination, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-05-10 | — | — | US | disclosed |
| US-5216164-A | Used for relieving memory dysfunction such as Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0489379-A1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| US-5110815-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | GRM5 3952/4885ALDH1A1 1758/4885MAPK1 3732/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | GRM5 2128/4885ALDH1A1 2096/4885MAPK1 3297/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | GRM5 2413/4885ALDH1A1 1849/4885MAPK1 3486/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | GRM5 2128/4885ALDH1A1 2096/4885MAPK1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.